Alpha 2.0
Login Register
» Authors » Suzanne Leijen

Suzanne Leijen

Explore the profile of Suzanne Leijen including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 658
Followers 0
Related Specialties
Oncology
Biochemistry
Pharmacology
Top 10 Co-Authors
Jan H M Schellens
Jos H Beijnen
Nadine Houede
Jean-Pierre Delord
Philippe Aftimos
Richard Kefford
Ahmad Awada
Monica Dinulescu
Erik van Werkhoven
Mark A Lee
Published In
J Clin Oncol
Target Oncol
J Biol Chem
Cancer Chemother Pharmacol
Cancer Treat Rev
Affiliations
Soon will be listed here.
Recent Articles
1.
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Lebbe C, Italiano A, Houede N, Awada A, Aftimos P, Lesimple T, et al.
Target Oncol . 2020 Nov; 16(1):47-57. PMID: 33211315
Background: Pimasertib is a selective, potent mitogen-activated protein kinase kinase (MEK) 1/2 inhibitor. Objectives: The aim of this study was to describe the efficacy, safety, and pharmacodynamics of pimasertib at...
2.
Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
Delord J, Italiano A, Awada A, Aftimos P, Houede N, Lebbe C, et al.
Target Oncol . 2020 Nov; 16(1):37-46. PMID: 33170484
Background: The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-competitive MEK1/2 inhibitor. Objective:...
3.
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
Leijen S, van Geel R, Sonke G, de Jong D, Rosenberg E, Marchetti S, et al.
J Clin Oncol . 2016 Dec; 34(36):4354-4361. PMID: 27998224
Purpose AZD1775 is a first-in-class, potent, and selective inhibitor of WEE1 with proof of chemopotentiation in p53-deficient tumors in preclinical models. In a phase I study, the maximum tolerated dose...
4.
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
Leijen S, van Geel R, Pavlick A, Tibes R, Rosen L, Abdul Razak A, et al.
J Clin Oncol . 2016 Sep; 34(36):4371-4380. PMID: 27601554
Purpose AZD1775 is a WEE1 kinase inhibitor targeting G2 checkpoint control, preferentially sensitizing TP53-deficient tumor cells to DNA damage. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of...
5.
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
Leijen S, Burgers S, Baas P, Pluim D, Tibben M, van Werkhoven E, et al.
Invest New Drugs . 2014 Oct; 33(1):201-14. PMID: 25344453
Background: This phase I/II study determined the maximal tolerable dose, dose limiting toxicities, antitumor activity, the pharmacokinetics and pharmacodynamics of ruthenium compound NAMI-A in combination with gemcitabine in Non-Small Cell...
6.
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer
Leijen S, Veltkamp S, Huitema A, van Werkhoven E, Beijnen J, Schellens J
Gynecol Oncol . 2013 May; 130(3):511-7. PMID: 23665458
Objective: This phase I study of fixed dose rate (FDR) gemcitabine and carboplatin assessed the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), safety, pharmacokinetic (PK)/pharmacodynamic (PD) profile and preliminary anti-tumor...
7.
Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities
van der Noll R, Leijen S, Neuteboom G, Beijnen J, Schellens J
Cancer Treat Rev . 2013 Feb; 39(6):664-72. PMID: 23434072
By the introduction of molecularly targeted anti-cancer drugs, that are designed to intervene with specific pathways aberrant in cancers with distinct mutations, the type of adverse events encountered has changed...
8.
Evaluation of dried blood spot (DBS) technology versus plasma analysis for the determination of MK-1775 by HILIC-MS/MS in support of clinical studies
Xu Y, Fang W, Zeng W, Leijen S, Woolf E
Anal Bioanal Chem . 2012 Oct; 404(10):3037-48. PMID: 23099526
The collection of human blood samples as dried blood spots (DBS) for the pharmacokinetic assessment of investigational drugs in clinical trials offers a number of advantages over conventional plasma sampling,...
9.
Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors
Leijen S, Middleton M, Tresca P, Kraeber-Bodere F, Dieras V, Scheulen M, et al.
Clin Cancer Res . 2012 Jul; 18(17):4794-805. PMID: 22767668
Purpose: This phase I study of the mitogen-activated protein/extracellular signal-regulated kinase inhibitor RO4987655 (CH4987655) assessed its maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetic/pharmacodynamic profile, and antitumor activity in...
10.
A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
Leijen S, Soetekouw P, Evans T, Nicolson M, Schellens J, Learoyd M, et al.
Cancer Chemother Pharmacol . 2011 Sep; 68(6):1619-28. PMID: 21953275
Purpose: This Phase I study assessed whether food influences the rate and extent of selumetinib absorption in patients with advanced solid malignancies and determined the safety, tolerability, and pharmacokinetic (PK)...